Table 1.

Prediction of the biomarkers

Biomarker	Prediction
Her2 heterogeneity	Worse DFS and OS [20, 21]
Her2 expression	Better PFS [22, 23, 24]
Her2 mutations
P780-Y781	Resistance to lapatinib [27]
T798M	Resistance to lapatinib [28]
L755S	Her2 reactivation during treatment [29]
CHD 1	ILC worse OS and DFS [30]
P95Her2	Worse OS and DFS [32]
Hormone receptor	Better OS and DFS [35, 36, 38]
ER positivity	Better OS and DFS [3, 37]
PR positivity	Unclear [3, 32]
PIK3CA mutation	Controversial data [15, 22, 23, 34, 43, 44, 45, 46]
PTEN	No effect [23, 47, 48, 49, 50]
PD-L1	Controversial data [51, 52, 53, 54]
TIL	Higher pCR rates Association with better DFS and OS [51, 56, 59, 60]
BRCA	No data about its prognostic impact up to date
miRNA
Downregulation of miR-342	Resistance to tamoxifen [67]
Upregulation of miR-221	Resistance to tamoxifen [68]
Upregulation of miR-222	Resistance to tamoxifen [68]